Association of funding and conclusions in randomized drug trials: a reflection of treatment effect or adverse events?
- PMID: 12928469
- DOI: 10.1001/jama.290.7.921
Association of funding and conclusions in randomized drug trials: a reflection of treatment effect or adverse events?
Abstract
Context: Previous studies indicate that industry-sponsored trials tend to draw proindustry conclusions.
Objective: To explore whether the association between funding and conclusions in randomized drug trials reflects treatment effects or adverse events.
Design: Observational study of 370 randomized drug trials included in meta-analyses from Cochrane reviews selected from the Cochrane Library, May 2001. From a random sample of 167 Cochrane reviews, 25 contained eligible meta-analyses (assessed a binary outcome; pooled at least 5 full-paper trials of which at least 1 reported adequate and 1 reported inadequate allocation concealment). The primary binary outcome from each meta-analysis was considered the primary outcome for all trials included in each meta-analysis. The association between funding and conclusions was analyzed by logistic regression with adjustment for treatment effect, adverse events, and additional confounding factors (methodological quality, control intervention, sample size, publication year, and place of publication).
Main outcome measure: Conclusions in trials, classified into whether the experimental drug was recommended as the treatment of choice or not.
Results: The experimental drug was recommended as treatment of choice in 16% of trials funded by nonprofit organizations, 30% of trials not reporting funding, 35% of trials funded by both nonprofit and for-profit organizations, and 51% of trials funded by for-profit organizations (P<.001; chi2 test). Logistic regression analyses indicated that funding, treatment effect, and double blinding were the only significant predictors of conclusions. Adjusted analyses showed that trials funded by for-profit organizations were significantly more likely to recommend the experimental drug as treatment of choice (odds ratio, 5.3; 95% confidence interval, 2.0-14.4) compared with trials funded by nonprofit organizations. This association did not appear to reflect treatment effect or adverse events.
Conclusions: Conclusions in trials funded by for-profit organizations may be more positive due to biased interpretation of trial results. Readers should carefully evaluate whether conclusions in randomized trials are supported by data.
Comment in
-
Results of clinical trials sponsored by for-profit vs nonprofit entities.JAMA. 2003 Dec 17;290(23):3070; author reply 3071-2. doi: 10.1001/jama.290.23.3070-b. JAMA. 2003. PMID: 14679266 No abstract available.
-
Results of clinical trials sponsored by for-profit vs nonprofit entities.JAMA. 2003 Dec 17;290(23):3070-1; author reply 3071-2. doi: 10.1001/jama.290.23.3070-c. JAMA. 2003. PMID: 14679267 No abstract available.
-
Results of clinical trials sponsored by for-profit vs nonprofit entities.JAMA. 2003 Dec 17;290(23):3071; author reply 3071-2. doi: 10.1001/jama.290.23.3071-a. JAMA. 2003. PMID: 14679268 No abstract available.
Similar articles
-
The association of funding source on effect size in randomized controlled trials: 2013-2015 - a cross-sectional survey and meta-analysis.Trials. 2017 Mar 14;18(1):125. doi: 10.1186/s13063-017-1872-0. Trials. 2017. PMID: 28292317 Free PMC article.
-
Financial conflicts of interest and their association with outcome and quality of fibromyalgia drug therapy randomized controlled trials.Int J Rheum Dis. 2015 Jul;18(6):606-15. doi: 10.1111/1756-185X.12607. Epub 2015 May 27. Int J Rheum Dis. 2015. PMID: 26012523
-
Reported outcomes in major cardiovascular clinical trials funded by for-profit and not-for-profit organizations: 2000-2005.JAMA. 2006 May 17;295(19):2270-4. doi: 10.1001/jama.295.19.2270. JAMA. 2006. PMID: 16705108
-
Reporting of conflicts of interest in meta-analyses of trials of pharmacological treatments.JAMA. 2011 Mar 9;305(10):1008-17. doi: 10.1001/jama.2011.257. JAMA. 2011. PMID: 21386079 Review.
-
DEPERROR: Risks of systematic errors in drug and non-drug randomized clinical trials assessing intervention effects in patients with unipolar depression.J Affect Disord. 2015 Jul 1;179:121-7. doi: 10.1016/j.jad.2015.03.042. Epub 2015 Apr 1. J Affect Disord. 2015. PMID: 25863907 Review.
Cited by
-
Conflict of interest policies for organizations producing a large number of clinical practice guidelines.PLoS One. 2012;7(5):e37413. doi: 10.1371/journal.pone.0037413. Epub 2012 May 22. PLoS One. 2012. PMID: 22629391 Free PMC article.
-
Improving transparency and scientific rigor in academic publishing.Cancer Rep (Hoboken). 2019 Feb;2(1):e1150. doi: 10.1002/cnr2.1150. Epub 2018 Dec 2. Cancer Rep (Hoboken). 2019. PMID: 32721132 Free PMC article.
-
Is microfracture sufficient for high-tibial osteotomy, or should intra-articular hyaluronic acid and oral glucosamine-chondroitin be used as additional treatments?J Orthop Surg Res. 2024 Sep 28;19(1):601. doi: 10.1186/s13018-024-05095-y. J Orthop Surg Res. 2024. PMID: 39342338 Free PMC article.
-
Ghost authorship in industry-initiated randomised trials.PLoS Med. 2007 Jan;4(1):e19. doi: 10.1371/journal.pmed.0040019. PLoS Med. 2007. PMID: 17227134 Free PMC article.
-
Assessment of Pharmaceutical Company and Device Manufacturer Payments to Gastroenterologists and Their Participation in Clinical Practice Guideline Panels.JAMA Netw Open. 2018 Dec 7;1(8):e186343. doi: 10.1001/jamanetworkopen.2018.6343. JAMA Netw Open. 2018. PMID: 30646328 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources